Nymox Pharmaceutical Corp. (NYMX)

2.70
0.23 9.30
NASDAQ : Health Technology
Prev Close 2.47
Open 2.50
Day Low/High 2.37 / 2.72
52 Wk Low/High 1.25 / 4.60
Volume 100.17K
Avg Volume 81.70K
Exchange NASDAQ
Shares Outstanding 63.72M
Market Cap 158.02M
EPS -0.30
Div & Yield N.A. (N.A)

Nymox To Present At Singular Research Annual "Best Of The Uncovereds" Research Conference

Conference Scheduled for Thursday, November 4, 2010 in Los Angeles

Bankruptcy Watch: Stocks Under $5

Bankruptcy Watch: Stocks Under $5

For these stocks trading for less than $5, a bankruptcy filing within two years is a probability.

Under $5 Stocks at Risk of Defaulting

Under $5 Stocks at Risk of Defaulting

For these stocks trading for less than $5, a bankruptcy filing within two years is a probability.

Nymox Announces New U.S. Follow-Up Results From Study NX02-0014, BPH Drug NX-1207 Continues To Show Positive Data At 5 Years

Efficacy From Single Treatment for Enlarged Prostate Maintains Statistical Significance at 5 Years

New Positive Data On NX-1207 Presented At Symposium At American Urological Association Annual Meeting

Symposium, New Data Presentation, and Panel Discussion Highlight New Treatment for BPH

Nymox NX-1207 Symposium At American Urological Association Annual Meeting In San Francisco Tuesday June 1 At 3:00 P.m. PDT

Symposium to Include Podium Presentations, New Data and Panel Discussion Featuring Distinguished U.S. Urologists

Nymox Announces 3 Year Follow-Up Results From NX02-0016 U.S. Study Of NX-1207 For BPH

Statistical Significance for Efficacy Reached 3 Years Post Single Treatment, Indicates Durable Clinical Response to New Therapy for Enlarged Prostate

Nymox Pharmaceuticals Gets $15M Financing Deal

Nymox Pharmaceuticals Gets $15M Financing Deal

Nymox Phamaceuticals announces $15 million equity financing deal

Small-Cap Winners & Losers: Rimage

Rimage slides on lowered forward guidance.

Wednesday's Health Winners & Losers

PDL BioPharma sinks on a refocused business plan.

Feuerstein's Biotech-Stock Mailbag

This week, questions on Genitope, Immunogen and Nymox. Plus, is Adam really that negative?

Tuesday's Small-Cap Winners & Losers

InsWeb rises.

Health Stocks in Motion

Geron rises on Merck licensing deal.

Health Stocks in Motion

Forbes Medi-Tech rises on new supply pact.

TheStreet Quant Rating: E+ (Sell)